NCT02704754View on ClinicalTrials.gov

Suvorexant and Trauma Related Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 1, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
InsomniaPosttraumatic Stress Disorder
Interventions
DRUG

suvorexant

First in class orexin antagonist recently approved by the FDA for the treatment of insomnia

OTHER

placebo

Pill with inactive ingredients

Trial Locations (1)

20060

Clinical Research Unit; Howard University Hospital, Washington D.C.

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Howard University

OTHER

NCT02704754 - Suvorexant and Trauma Related Insomnia | Biotech Hunter | Biotech Hunter